Introduction

Colorectal cancer (CRC) is among the most prevalent cancers worldwide. Treatment with monoclonal antibodies against Epidermal Growth Factor Receptor (Anti-EGFR) has shown to be effective for CRC patients. However, Anti-EGFR would be in- effective in presence of some KRAS mutations including mutations in codons 12 and 13. This is the same for treating non small cell lung cancer (NSCLC) with Anti-EGFR. Therefore, determining the KRAS mutation status is essential for these patients. It should be noted that, 95% and 88% of KRAS mutations in CRC and NSCLC patients respectively are reported in codons 12 and 13 including G12A, G12C, G12D, G12R, G12S, G12V and G13D.

KRAS RQ Kit provides ready to use mixes for detection of these 7 mutations based on Real-Time PCR technology. In this method application of fluorescent probes allows detection of amplified product. Analysis of fluorescent kinetics also leads to detection of the target sequence in the reaction without requiring post- amplification analysis, reducing the possibility of contamination with the PCR product. This kit also takes advantage of Internal control for preventing false negative results due to failure in DNA extraction or PCR reaction. This kit is designed to be used with Rotor-Gene.